Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  OpGen, Inc.    OPGN

OPGEN, INC.

(OPGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

OPGEN : Financial Statements and Exhibits (form 8-K/A)

06/15/2020 | 05:09pm EST

Item 9.01 Financial Statements and Exhibits.

(a) Financial statements of business acquired

The consolidated financial statements and financial statement schedules of the Curetis Business as of December 31, 2019 and 2018 and for each of the years in the two-year period ended December 31, 2019 and the notes related thereto, are attached hereto as Exhibit 99.1 and are incorporated by reference herein. The consent of PricewaterhouseCoopers GmbH Wirtschaftsprüfungsgesellschaft, the Curetis Business' independent registered public accounting firm, is attached as Exhibit 23.1 to this Current Report on Form 8-K/A.

(b) Pro forma financial information

The unaudited pro forma condensed combined financial information of OpGen, giving effect to the acquisition of Curetis, which includes the unaudited pro forma condensed combined balance sheet as of March 31, 2020, the unaudited pro forma condensed combined statements of earnings for the year ended December 31, 2019 and for the three months ended March 31, 2020 and the notes related thereto, are attached hereto as Exhibit 99.2 and are incorporated herein by reference.


(d) Exhibits

Exhibit No.   Document
23.1            Consent of PricewaterhouseCoopers GmbH
              Wirtschaftsprüfungsgesellschaft
99.1            Curetis Business Audited Historical Consolidated Financial Statements
              and Related Notes
99.2            OpGen, Inc. Unaudited Pro Forma Condensed Combined Financial
              Statements and Related Notes

© Edgar Online, source Glimpses

All news about OPGEN, INC.
11/24OPGEN INC : Entry into a Material Definitive Agreement, Unregistered Sale of Equ..
AQ
11/24OPGEN : Announces $10 Million Private Placement Priced at the Market
AQ
11/24OpGen, Inc. Announces $10 Million Private Placement Priced at the Market
GL
11/16OPGEN : Note 2 - Liquidity and management's plans
AQ
11/13OPGEN : Corporate Presentation (PDF)
PU
11/13OPGEN INC : Entry into a Material Definitive Agreement, Other Events, Financial ..
AQ
11/12OPGEN : Ares Genetics Commercially Launches NGS-based Antibiotic Resistance Test..
AQ
11/12OpGen Group Company Ares Genetics Commercially Launches NGS-based Antibiotic ..
GL
11/12OPGEN INC : Results of Operations and Financial Condition, Financial Statements ..
AQ
11/11OPGEN : Reports Third Quarter 2020 Financial Results and Provides Business Updat..
AQ
More news
Financials (USD)
Sales 2020 4,12 M - -
Net income 2020 -24,8 M - -
Net Debt 2020 - - -
P/E ratio 2020 -1,16x
Yield 2020 -
Capitalization 39,5 M 39,5 M -
Capi. / Sales 2020 9,58x
Capi. / Sales 2021 3,53x
Nbr of Employees 39
Free-Float 99,9%
Chart OPGEN, INC.
Duration : Period :
OpGen, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OPGEN, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Average target price 5,33 $
Last Close Price 1,96 $
Spread / Highest target 188%
Spread / Average Target 172%
Spread / Lowest Target 155%
EPS Revisions
Managers
NameTitle
Oliver Schacht Chief Executive Officer & Director
Bill E. Rhodes Non-Executive Chairman
Johannes Bacher Chief Operating Officer
Timothy C. Dec CFO, Secretary & Chief Accounting Officer
Vadim Sapiro Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
OPGEN, INC.73.45%40
LONZA GROUP AG56.17%44 950
MODERNA, INC.403.89%39 001
CELLTRION, INC.82.32%36 284
IQVIA HOLDINGS INC.11.32%32 977
SEAGEN INC.44.08%29 684